Answers are grounded in this paper and cite their sources.
The primary aim of this study was to examine the benefit of extending adjuvant temozolomide (TMZ) duration beyond six cycles in newly diagnosed glioblastoma (GBM) measured by progression free survival (PFS) and overall survival (OS).
No takes yet. Share an insight, caveat, or question.
Barnett et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: